𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Early rasagiline keeps up TEMPO long term in Parkinson's disease

Book ID
120854715
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2005
Weight
120 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Long-term outcome of early versus delaye
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
✍ Robert A. Hauser; Mark F. Lew; Howard I. Hurtig; William G. Ondo; Joanne Wojcies πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 329 KB πŸ‘ 1 views

## Abstract The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasa

Rasagiline improves quality of life in p
Rasagiline improves quality of life in patients with early Parkinson's disease
✍ Kevin M. Biglan; Steven Schwid; Shirley Eberly; Karen Blindauer; Stanley Fahn; T πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 164 KB πŸ‘ 1 views

The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early P